Somatostatin does not block the effect of vasoactive intestinal peptide on bile secretion in man.

Nyberg B, Angelin B, Einarsson K

European journal of clinical investigation1 Jan 1992Cited by 3 (Europe PMC)

PMID1348475DOI10.1111/j.1365-2362.1992.tb01937.xPepBankPUB-01348475

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with complete biliary fistulas, intravenous VIP infusion increased bile secretion by 85%.
In plain wordsIn people with biliary fistulas, VIP given into a vein increased bile secretion by 85%.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseBile secretion during VIP infusion
Study
n = 10
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intravenousAs given in this study (human).
Measurements
Bile secretion increase
85%
VIP infusion
Source sentences
Summary
During the infusion of vasoactive intestinal peptide, bile secretion increased by 85%
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of intravenously administered somatostatin and vasoactive intestinal peptide (VIP) on bile secretion were studied in 10 patients with complete biliary fistulas.
Report a problemFND-0134847501
02HumanNon-randomized trialEfficacy outcome
In patients with biliary fistulas, VIP infusion increased bile bicarbonate concentration.
In plain wordsIn people with biliary fistulas, VIP raised the bicarbonate concentration in bile.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseBicarbonate concentration during VIP infusion
Study
n = 10
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Vasoactive intestinal peptide infusion increased bicarbonate concentration and output
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of intravenously administered somatostatin and vasoactive intestinal peptide (VIP) on bile secretion were studied in 10 patients with complete biliary fistulas.
Report a problemFND-0134847503
03HumanNon-randomized trialEfficacy outcome
In patients with biliary fistulas, VIP infusion increased bile bicarbonate output.
In plain wordsIn people with biliary fistulas, VIP raised the amount of bicarbonate released in bile.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseBicarbonate output during VIP infusion
Study
n = 10
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
Vasoactive intestinal peptide infusion increased bicarbonate concentration and output
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of intravenously administered somatostatin and vasoactive intestinal peptide (VIP) on bile secretion were studied in 10 patients with complete biliary fistulas.
Report a problemFND-0134847504
04HumanNon-randomized trialEfficacy outcome
In patients with biliary fistulas, the output of chloride in bile increased following VIP infusion.
In plain wordsIn people with biliary fistulas, VIP raised the amount of chloride released in bile.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseChloride output during VIP infusion
Study
n = 10
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
The output of chloride also increased following vasoactive intestinal peptide infusion
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of intravenously administered somatostatin and vasoactive intestinal peptide (VIP) on bile secretion were studied in 10 patients with complete biliary fistulas.
Report a problemFND-0134847505
05HumanNon-randomized trialEfficacy outcome
In patients with biliary fistulas, VIP infusion decreased the concentration of chloride in bile.
In plain wordsIn people with biliary fistulas, VIP lowered the chloride concentration in bile.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseChloride concentration during VIP infusion
Study
n = 10
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
The concentration of chloride was unaffected by somatostatin whereas it was decreased by vasoactive intestinal peptide.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of intravenously administered somatostatin and vasoactive intestinal peptide (VIP) on bile secretion were studied in 10 patients with complete biliary fistulas.
Report a problemFND-0134847506
06HumanNon-randomized trialEfficacy outcome
In patients with biliary fistulas, the output of bile acids was unaffected by VIP.
In plain wordsIn people with biliary fistulas, VIP did not change the output of bile acids.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeBile acid output during VIP infusion
Study
n = 10
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
The output of bile acids was unaffected by vasoactive intestinal peptide
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of intravenously administered somatostatin and vasoactive intestinal peptide (VIP) on bile secretion were studied in 10 patients with complete biliary fistulas.
Report a problemFND-0134847507

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

07HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialEfficacy outcome
In patients with biliary fistulas, when VIP and somatostatin were infused together, the VIP-induced choleretic effect was not reduced by somatostatin.
In plain wordsIn people with biliary fistulas, somatostatin given with VIP did not reduce VIP's bile-increasing effect.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP-induced choleretic effect with simultaneous somatostatin
Study
n = 10
Comparator
VIP alone
Outcome group
Gastrointestinal function · Gastrointestinal
Source sentences
Summary
When the peptides were administered together, the VIP-induced choleretic effect was not reduced by somatostatin.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of intravenously administered somatostatin and vasoactive intestinal peptide (VIP) on bile secretion were studied in 10 patients with complete biliary fistulas.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0134847502
08HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialEfficacy outcome
In patients with biliary fistulas, total lipid concentration in bile, which increased during somatostatin infusion, decreased when VIP was added.
In plain wordsIn people with biliary fistulas, adding VIP to somatostatin lowered the lipid concentration in bile that somatostatin had raised.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseTotal lipid concentration when VIP was added to somatostatin
Study
n = 10
Comparator
Somatostatin alone
Outcome group
Gastrointestinal function · Gastrointestinal
Source sentences
Summary
total lipid concentration increased during somatostatin infusion and decreased when vasoactive intestinal peptide was added.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of intravenously administered somatostatin and vasoactive intestinal peptide (VIP) on bile secretion were studied in 10 patients with complete biliary fistulas.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0134847508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.